Bio Techne Valuation
| TECH Stock | USD 67.63 0.53 0.78% |
At this time, the firm appears to be fairly valued. Bio Techne Corp shows a prevailing Real Value of $67.96 per share. The current price of the firm is $67.63. Our model approximates the value of Bio Techne Corp from analyzing the firm fundamentals such as Current Valuation of 10.87 B, profit margin of 0.06 %, and Return On Equity of 0.038 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bio Techne's valuation include:
Price Book 5.4024 | Enterprise Value | Enterprise Value Ebitda 49.0386 | Price Sales 8.7285 | Forward PE 34.2466 |
Fairly Valued
Today
Please note that Bio Techne's price fluctuation is very steady at this time. Calculation of the real value of Bio Techne Corp is based on 3 months time horizon. Increasing Bio Techne's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bio Techne is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio Stock. However, Bio Techne's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 67.63 | Real 67.96 | Target 70.0 | Hype 67.68 |
The intrinsic value of Bio Techne's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Bio Techne's stock price.
Estimating the potential upside or downside of Bio Techne Corp helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Techne more accurately as focusing exclusively on Bio Techne's fundamentals will not take into account other important factors: When choosing an evaluation method for Bio Techne Corp, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Bio Techne Cash |
|
Bio Revenue by Product
Bio Techne Total Value Analysis
Bio Techne Corp is at this time forecasted to have valuation of 10.87 B with market capitalization of 10.62 B, debt of 444.06 M, and cash on hands of 247.03 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Bio Techne fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.87 B | 10.62 B | 444.06 M | 247.03 M |
Bio Techne Investor Information
About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.83. Bio Techne Corp last dividend was issued on the 17th of November 2025. The entity had 4:1 split on the 30th of November 2022. Based on the measurements of operating efficiency obtained from Bio Techne's historical financial statements, Bio Techne Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.0717 | 0.0755 |
|
| |||||
| Total Cash From Operating Activities | 347.2 M | 330.7 M |
|
| |||||
| Operating Income | 113.1 M | 117.6 M |
|
|
Bio Techne Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bio Techne has an asset utilization ratio of 47.68 percent. This signifies that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Bio Techne Corp is more efficient with each dollar of assets it utilizes for everyday operations.Bio Techne Profitability Analysis
Based on the measurements of profitability obtained from Bio Techne's financial statements, Bio Techne Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in February. Profitability indicators assess Bio Techne's ability to earn profits and add value for shareholders.Net Income | First Reported 1989-09-30 | Previous Quarter -17.7 M | Current Value 38.2 M | Quarterly Volatility 20.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.56 | 0.58 |
|
| |||||
| Net Profit Margin | 0.0515 | 0.0542 |
|
| |||||
| Operating Profit Margin | 0.0717 | 0.0755 |
|
| |||||
| Pretax Profit Margin | 0.069 | 0.0727 |
|
| |||||
| Return On Assets | 0.0314 | 0.033 |
|
| |||||
| Return On Equity | 0.0418 | 0.044 |
|
|
For Bio Techne profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bio Techne Corp to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bio Techne utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bio Techne's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bio Techne over time as well as its relative position and ranking within its peers.
Bio Techne Earnings per Share Projection vs Actual
The next projected EPS of Bio Techne is estimated to be 0.5633 with future projections ranging from a low of 0.53 to a high of 0.6. Bio Techne's most recent 12-month trailing earnings per share (EPS TTM) is at 0.49. Please be aware that the consensus of earnings estimates for Bio Techne Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Bio Techne Earnings Estimation Breakdown
The calculation of Bio Techne's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Bio Techne is estimated to be 0.5633 with the future projection ranging from a low of 0.53 to a high of 0.6. Please be aware that this consensus of annual earnings estimates for Bio Techne Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.53 Lowest | Expected EPS | 0.60 Highest |
Bio Techne Earnings Projection Consensus
Suppose the current estimates of Bio Techne's value are higher than the current market price of the Bio Techne stock. In this case, investors may conclude that Bio Techne is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Bio Techne's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 15 | 89.02% | 0.0 | 0.5633 | 0.49 |
Bio Techne Ownership Allocation
The majority of Bio Techne Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Techne Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Techne. Please pay attention to any change in the institutional holdings of Bio Techne Corp as this could imply that something significant has changed or is about to change at the company. On January 6, 2026, Representative April Delaney of US Congress acquired under $15k worth of Bio Techne Corp's common stock.Bio Techne Profitability Analysis
The company reported the previous year's revenue of 1.22 B. Net Income was 73.4 M with profit before overhead, payroll, taxes, and interest of 813.2 M.Bio Techne Past Distributions to stockholders
About Bio Techne Valuation
An absolute valuation paradigm, as applied to Bio Stock, attempts to find the value of Bio Techne Corp based on its fundamental and basic technical indicators. By analyzing Bio Techne's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bio Techne's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bio Techne. We calculate exposure to Bio Techne's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bio Techne's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 908.8 M | 954.3 M | |
| Pretax Profit Margin | 0.07 | 0.07 | |
| Operating Profit Margin | 0.08 | 0.07 | |
| Net Profit Margin | 0.05 | 0.05 | |
| Gross Profit Margin | 0.58 | 0.56 |
Bio Techne Quarterly Retained Earnings |
|
A single share of Bio Techne represents a small ownership stake in the entity. As a stockholder of Bio, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Bio Techne Dividends Analysis For Valuation
As of now, Bio Techne's Dividend Yield is decreasing as compared to previous years. The Bio Techne's current Dividend Payout Ratio is estimated to increase to 0.65, while Dividends Paid is forecasted to increase to (43.1 M). . As of now, Bio Techne's Retained Earnings are increasing as compared to previous years. The Bio Techne's current Price Earnings Ratio is estimated to increase to 104.34, while Retained Earnings Total Equity is projected to decrease to under 812.3 M.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | -45.4 M | -43.1 M | |
| Dividend Yield | 0.01 | 0.01 | |
| Dividend Payout Ratio | 0.62 | 0.65 | |
| Dividend Paid And Capex Coverage Ratio | 4.06 | 4.81 |
There are various types of dividends Bio Techne can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Bio shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Bio Techne Corp directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Bio pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Bio Techne by the value of the dividends paid out.
Bio Techne Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 159.7 M | |
| Quarterly Earnings Growth Y O Y | 0.143 | |
| Forward Price Earnings | 34.2466 |
Bio Techne Current Valuation Indicators
Valuation refers to the process of determining the present value of Bio Techne Corp and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bio we look at many different elements of the entity such as Bio's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bio Techne, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bio Techne's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bio Techne's worth.Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |